Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)
(2017) In Gynecologic Oncology 144(1). p.167-173- Abstract
Objective: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. Methods: Nation-wide population-based study of women. ≥. 18. years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method. Simple and multivariable analyses were estimated by Poisson regression models. Results: Of 5627 women identified, 1246 (22%) had borderline tumors and 4381 had malignant tumors. In total, 2359 women had serous cancer; 71% originated in the ovary (OC), 9% in the... (More)
Objective: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. Methods: Nation-wide population-based study of women. ≥. 18. years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method. Simple and multivariable analyses were estimated by Poisson regression models. Results: Of 5627 women identified, 1246 (22%) had borderline tumors and 4381 had malignant tumors. In total, 2359 women had serous cancer; 71% originated in the ovary (OC), 9% in the fallopian tube (FTC), 9% in the peritoneum (PPC) and 11% at an undesignated primary site (UPS). Estimated RS at 5-years was 37%; for FTC 54%, 40% for OC, 34% for PPC and 13% for UPS. In multivariable regression analyses restricted to women who had undergone primary or interval debulking surgery for OC, FTC and PPC, site of origin was not independently associated with survival. Significant associations with worse survival were found for advanced stages (RR 2.63, . P . <. 0.001), moderate (RR 1.90, . P . <. 0.047) and poor differentiation (RR 2.20, . P . <. 0.009), neoadjuvant chemotherapy (RR1.33, . P . <. 0.022), residual tumor (RR 2.65, . P . <. 0.001) and platinum single (2.34, . P . <. 0.001) compared to platinum combination chemotherapy. Conclusion: Survival was poorer for serous cancer at UPS than for ovarian, fallopian tube and peritoneal cancer. Serous cancer at UPS needs to be addressed when reporting and comparing survival rates of ovarian cancer.
(Less)
- author
- organization
- publishing date
- 2017
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cancer origin, Ovarian cancer, Serous cancer, Survival
- in
- Gynecologic Oncology
- volume
- 144
- issue
- 1
- pages
- 167 - 173
- publisher
- Academic Press
- external identifiers
-
- scopus:85005865079
- pmid:27817932
- wos:000392367000030
- ISSN
- 0090-8258
- DOI
- 10.1016/j.ygyno.2016.10.039
- language
- English
- LU publication?
- yes
- id
- b6c6c2ea-17ae-41b1-b092-a2e729937efc
- date added to LUP
- 2016-12-30 09:25:29
- date last changed
- 2024-04-19 17:14:33
@article{b6c6c2ea-17ae-41b1-b092-a2e729937efc,
abstract = {{<p>Objective: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. Methods: Nation-wide population-based study of women. ≥. 18. years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method. Simple and multivariable analyses were estimated by Poisson regression models. Results: Of 5627 women identified, 1246 (22%) had borderline tumors and 4381 had malignant tumors. In total, 2359 women had serous cancer; 71% originated in the ovary (OC), 9% in the fallopian tube (FTC), 9% in the peritoneum (PPC) and 11% at an undesignated primary site (UPS). Estimated RS at 5-years was 37%; for FTC 54%, 40% for OC, 34% for PPC and 13% for UPS. In multivariable regression analyses restricted to women who had undergone primary or interval debulking surgery for OC, FTC and PPC, site of origin was not independently associated with survival. Significant associations with worse survival were found for advanced stages (RR 2.63, . P . <. 0.001), moderate (RR 1.90, . P . <. 0.047) and poor differentiation (RR 2.20, . P . <. 0.009), neoadjuvant chemotherapy (RR1.33, . P . <. 0.022), residual tumor (RR 2.65, . P . <. 0.001) and platinum single (2.34, . P . <. 0.001) compared to platinum combination chemotherapy. Conclusion: Survival was poorer for serous cancer at UPS than for ovarian, fallopian tube and peritoneal cancer. Serous cancer at UPS needs to be addressed when reporting and comparing survival rates of ovarian cancer.</p>}},
author = {{Dahm-Kähler, Pernilla and Borgfeldt, Christer and Holmberg, Erik and Staf, Christian and Falconer, Henrik and Bjurberg, Maria and Kjölhede, Preben and Rosenberg, Per and Stålberg, Karin and Högberg, Thomas and Åvall-Lundqvist, Elisabeth}},
issn = {{0090-8258}},
keywords = {{Cancer origin; Ovarian cancer; Serous cancer; Survival}},
language = {{eng}},
number = {{1}},
pages = {{167--173}},
publisher = {{Academic Press}},
series = {{Gynecologic Oncology}},
title = {{Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG)}},
url = {{http://dx.doi.org/10.1016/j.ygyno.2016.10.039}},
doi = {{10.1016/j.ygyno.2016.10.039}},
volume = {{144}},
year = {{2017}},
}